Heidelberg Pharma AG
XETRA: HPHA.DE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Deutsche Börse
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dongzhou Liu
- Employees
- 105
- Headquarters
- Ladenburg, Germany
- IPO year
- 2006
- Market cap
- €127.7M
- Website
- https://heidelberg-pharma.com
Loading HPHA…
Loading profile data…Frequently asked questions about HPHA
What does Heidelberg Pharma AG (HPHA.DE) do?
Heidelberg Pharma AG, a biopharmaceutical company, focuses on oncology and antibody targeted amanitin conjugates (ATAC) in Germany, other European countries, the United States, and internationally. Its lead product candidate is HDP-101, which in the Phase I/IIa study for the treatment of relapsed or refractory multiple myeloma. It is developing...
Where does HPHA.DE trade?
Heidelberg Pharma AG (HPHA.DE) trades on the Deutsche Börse.
What sector is HPHA.DE in?
Heidelberg Pharma AG (HPHA.DE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Heidelberg Pharma AG?
Dongzhou Liu is the chief executive officer of Heidelberg Pharma AG (HPHA.DE).
Where is Heidelberg Pharma AG headquartered?
Heidelberg Pharma AG is headquartered in Germany.
Does HPHA.DE pay a dividend?
Heidelberg Pharma AG (HPHA.DE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HPHA.DE go public?
Heidelberg Pharma AG (HPHA.DE) completed its initial public offering in 2006.